Lazard Asset Management LLC Veracyte, Inc. Transaction History

Lazard Asset Management LLC

$63.4 Billion
Q2 2025

A detailed history of Lazard Asset Management LLC transactions in Veracyte, Inc. stock. As of the latest transaction made, Lazard Asset Management LLC holds 153,013 shares of VCYT stock, worth $5.45 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

153,013

Previous 122,327 25.09%

Holding current value

$5.45 Million

Previous $3.63 Million 14.04%

% of portfolio

0.01%

Previous 0.01%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	BUY	$26.39 - $32.62 $809,803 - $1 Million	30,686 Added 25.09%	153,013 $4.14 Million
Q1 2025 May 15, 2025	BUY	$29.65 - $46.14 $726,958 - $1.13 Million	24,518 Added 25.07%	122,327 $3.63 Million
Q4 2024 Feb 14, 2025	BUY	$31.92 - $44.4 $830,749 - $1.16 Million	26,026 Added 36.26%	97,809 $3.87 Million
Q3 2024 Nov 14, 2024	BUY	$21.0 - $35.25 $1.39 Million - $2.33 Million	66,121 Added 1167.8%	71,783 $2.44 Million
Q2 2024 Aug 14, 2024	SELL	$18.86 - $23.55 $13,315 - $16,626	-706 Reduced 11.09%	5,662 $122,000
Q1 2024 May 14, 2024	BUY	$21.0 - $29.1 $68,691 - $95,186	3,271 Added 105.62%	6,368 $140,000
Q4 2023 Feb 14, 2024	SELL	$19.72 - $28.68 $83,770 - $121,832	-4,248 Reduced 57.84%	3,097 $85,000
Q3 2023 Nov 14, 2023	BUY	$22.33 - $29.92 $84,295 - $112,948	3,775 Added 105.74%	7,345 $164,000
Q1 2023 May 15, 2023	SELL	$20.58 - $27.89 $1.08 Million - $1.46 Million	-52,242 Reduced 93.6%	3,570 $79,000
Q4 2022 Feb 14, 2023	BUY	$15.31 - $29.94 $540,703 - $1.06 Million	35,317 Added 172.32%	55,812 $1.32 Million
Q3 2022 Nov 14, 2022	BUY	$16.58 - $27.9 $267,750 - $450,557	16,149 Added 371.58%	20,495 $339,000
Q2 2022 Aug 09, 2022	BUY	$15.45 - $29.52 $14,461 - $27,630	936 Added 27.45%	4,346 $86,000
Q1 2022 May 13, 2022	BUY	$21.94 - $42.51 $23,673 - $45,868	1,079 Added 46.29%	3,410 $94,000
Q4 2021 Feb 09, 2022	BUY	$36.09 - $53.79 $32,336 - $48,195	896 Added 62.44%	2,331 $96,000
Q3 2021 Nov 15, 2021	BUY	$35.62 - $52.97 $51,114 - $76,011	1,435 New	1,435 $66,000
Q2 2021 Aug 12, 2021	SELL	$32.94 - $56.62 $55,240 - $94,951	-1,677 Closed	0 $0
Q1 2021 May 14, 2021	BUY	$44.47 - $81.38 $19,255 - $35,237	433 Added 34.81%	1,677 $90,000
Q4 2020 Feb 11, 2021	BUY	$32.49 - $61.88 $40,417 - $76,978	1,244 New	1,244 $60,000
Q3 2020 Nov 13, 2020	SELL	$26.73 - $35.67 $94,463 - $126,057	-3,534 Closed	0 $0
Q2 2020 Aug 13, 2020	BUY	$19.49 - $28.11 $68,877 - $99,340	3,534 New	3,534 $91,000
Q1 2020 May 14, 2020	SELL	$16.13 - $30.17 $35,211 - $65,861	-2,183 Closed	0 $0
Q4 2019 Feb 13, 2020	BUY	$20.78 - $29.99 $29,507 - $42,585	1,420 Added 186.11%	2,183 $60,000
Q3 2019 Nov 14, 2019	BUY	$23.87 - $30.93 $18,212 - $23,599	763 New	763 $18,000

Others Institutions Holding VCYT

# of Institutions

295

Shares Held

77.2M

Call Options Held

Put Options Held

17.6K

View Full List

About VERACYTE, INC.

Ticker VCYT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 71,575,904
Market Cap $2.55B
Description
Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer ...

More about VCYT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Lazard Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Lazard Asset Management LLC with notifications on news.

Account

Lazard Asset Management LLC Veracyte, Inc. Transaction History